Guofeng Liu

Guofeng Liu

Auto-generated profile, based on publicly available information

Guofeng Liu

From the Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China, scu.edu.cn

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Radiology
Verified
Journal Article
Closed access
XWXiaoze Wang
Xiaoze Wang
GLGuofeng Liu
Guofeng Liu
JWJunchao Wu
Junchao Wu
XXXue XIAO
Xue XIAO
YYYuling Yan
Yuling Yan
XLXuefeng Luo
Xuefeng Luo
Background Some studies have shown that transjugular intrahepatic portosystemic shunt (TIPS) placement within 72 hours of admission improves survival in patients at high risk who present with acute variceal bleeding. However, the role of small-diameter covered TIPS in the secondary prophylaxis of variceal bleeding is still debatable. Purpose To compare the efficacy of 8-mm TIPS and endoscopic variceal ligation (EVL) plus propranolol in the prevention of variceal rebleeding among participants with advanced cirrhosis. Materials and Methods Between June 2015 and December 2018, participants admitted to the hospital for variceal bleeding were considered for enrollment in this randomized controlled trial (ClinicalTrials.gov). Participants with Child-Pugh class B or C cirrhosis were randomly assigned to receive an 8-mm covered TIPS or EVL and propranolol. The primary end point was recurrent variceal bleeding assessed using Kaplan-Meier curve analysis. Secondary end points included survival and overt hepatic encephalopathy (HE) assessed using Kaplan-Meier curve analysis. Results A total of 100 participants were enrolled, with 50 randomly assigned to the EVL plus propranolol group (median age, 54 years; IQR, 45-60 years; 29 male, 21 female) and 50 randomly assigned to the TIPS group (median age, 49 years; IQR, 43-56 years; 32 male, 18 female). The median follow-up period was 43.4 months. In the TIPS group, variceal rebleeding risk was reduced compared with variceal rebleeding risk in the EVL plus propranolol group (hazard ratio [HR], 0.31; 95% CI: 0.14, 0.69; P = .008), but the incidence of overt HE was higher in the TIPS group (30.0% vs 16.0%, P = .03). No differences in survival were observed between the two groups (1-year survival: TIPS, 98.0%; EVL plus propranolol, 92.0%; 3-year survival: TIPS, 94.0%; EVL plus propranolol, 85.7%; HR, 0.52; 95% CI: 0.19, 1.42; P = .22). Conclusion When compared with EVL plus propranolol, 8-mm TIPS led to reduced variceal rebleeding but did not impact overall survival in participants with Child-Pugh class B or C cirrhosis. Clinical trial registration no. NCT02477384 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Barth in this issue.

1 February 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
GLGuofeng Liu
Guofeng Liu
SXSongchi Xiao
Songchi Xiao
TXTong Xiang
Tong Xiang
XWXiaoze Wang
Xiaoze Wang
YSYi Shen
Yi Shen
XLXuefeng Luo
Xuefeng Luo
Purpose: The treatment outcomes and risk factors for the prognosis of acute variceal bleeding (AVB) in hepatocellular carcinoma (HCC) patients remain unclear. Hence, we assessed the clinical outcomes and prognostic factors of these patients. Methods: This study retrospectively enrolled 1532 AVB patients with cirrhosis from January 2016 to December 2022. Of these patients, 310 had HCC, and after 1:1 individual matching, 306 of them were matched with 306 patients without HCC. Six-week mortality, one-year mortality, and five-day treatment failure were recorded. Results: In the matched-pair analysis, patients with HCC had a higher rate of 6-week and 1-year mortality than those without HCC (6-week: 24.5% vs 7.8%, P < 0.001; 1-year: 45.9% vs 16.2%, P < 0.001). The rate of 5-day treatment failure was similar between the two groups (21.1% vs 16.7%, P = 0.213). Among AVB patients with HCC, the multivariate analysis revealed that the Child-Pugh score (HR, 1.239, 95% CI, 1.121– 1.370; P < 0.001) and Barcelona Clinic Liver Cancer (BCLC) stage (C-D vs 0-B) (HR, 14.409; 95% CI, 5.758– 36.055; P < 0.001) were independently associated with 6-week mortality. Moreover, the rate of 6-week mortality was 60.2% in patients who had a high Child-Pugh score (≥ 9) and advanced BCLC stage (C–D), much higher than in those with low Child-Pugh score (< 9) and earlier BCLC stage (0-B) (P < 0.001). Conclusion: Among patients with cirrhosis and AVB, patients with HCC had significantly worse outcomes than those without. The severity of liver disease and the stage of HCC are the main determinants of mortality in HCC patients.

10 September 2025 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
GLGuofeng Liu
Guofeng Liu
SXSongchi Xiao
Songchi Xiao
XWXiaoze Wang
Xiaoze Wang
YSYi Shen
Yi Shen
YHYuping He
Yuping He
XLXuefeng Luo
Xuefeng Luo
Background: The optimal hemodynamic threshold for portal pressure gradient (PPG) following transjugular intrahepatic portosystemic shunt (TIPS) for ascites remains uncertain. Objective: This study aimed to elucidate the relationship between post-TIPS PPG and clinical outcomes in patients undergoing small-diameter (8-mm) TIPS for ascites. Design: Single-center retrospective study. Methods: From June 2015 to June 2023, consecutive patients receiving small-diameter (8-mm) TIPS for refractory or recurrent ascites were considered for inclusion retrospectively. The impact of PPG on clinical outcomes—including ascites response, overt hepatic encephalopathy (OHE), further decompensation, and mortality—was evaluated using Fine and Gray competing risk regression models, both unadjusted and adjusted for potential confounders. Results: A total of 143 patients were included in the analysis, of whom 65.7% had refractory ascites, with a median Child-Pugh score of 9. Receiver operating characteristic (ROC) curve analysis identified post-TIPS PPG as a reliable predictor of ascites response (cutoff: 10.5 mmHg, area under curves (AUC): 0.733, p < 0.001) and OHE (cutoff: 7.5 mmHg, AUC: 0.716, p < 0.001). Univariate and multivariate Fine and Gray competing risk regression analyses further revealed that patients with PPG between 8 and 10 mmHg had favorable outcomes, including a lower incidence of ascites (>10 vs 8–10 mmHg: hazard ratio (HR) = 5.74, 95% confidence interval (CI) 2.11–15.58, p < 0.001), a reduced risk of OHE (10 vs 8–10 mmHg: HR = 2.78, 95% CI 1.43–5.41, p = 0.003; <8 vs 8–10 mmHg: HR = 2.42, 95% CI 1.20–4.90, p = 0.014) after TIPS placement. Conclusion: This study revealed that post-TIPS PPG was associated with clinical outcomes in patients with refractory or recurrent ascites undergoing small-diameter TIPS. A post-TIPS PPG of 8–10 mmHg seems to be the optimal range, effectively controlling ascites without significantly increasing the risk of shunt-related hepatic encephalopathy, while also reducing the risk of further decompensation.

30 August 2025 in Liver International
Verified
Journal Article
Closed access
XWXiaoze Wang
Xiaoze Wang
JHJu Huang
Ju Huang
GLGuofeng Liu
Guofeng Liu
TXTong Xiang
Tong Xiang
YHYazhou He
Yazhou He
XLXuefeng Luo
Xuefeng Luo

1 January 2026 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
JHJiajia He
Jiajia He
JHJu Huang
Ju Huang
GLGuofeng Liu
Guofeng Liu
YHYuping He
Yuping He
XWXiaoze Wang
Xiaoze Wang
XLXuefeng Luo
Xuefeng Luo
Background & Aims: Prophylactic use of antibiotics was found to decrease mortality in patients with cirrhosis and acute variceal bleeding (AVB). Patients with Child A cirrhosis have a low risk of treatment failure and mortality. The present study was designed to investigate the association between antibiotics and Child–Pugh A patients with AVB. Methods: This retrospective analysis was conducted on Child–Pugh class A cirrhotic patients presenting with AVB at West China Hospital between January 2016 and November 2022. The outcome indicators evaluated in this study include the rate of treatment failure within five days, mortality within 6 weeks, incidence of nosocomial infections, and 1‐year cumulative mortality. Results: This study ultimately enrolled 237 patients. The day of patients’ admission was defined as Day 0. A total of 117 patients received prophylactic use of antibiotics on Days 0–1 (Group A), and 120 patients did not receive antibiotics on Days 0–1 (Group B). Baseline characteristics were well‐balanced between the two groups. The 5‐day treatment failure was 8.5% in Group A and 6.7% in Group B ( p = 0.63). The 6‐week mortality was 1.71% in Group A and 0% in Group B ( p = 0.24). The incidence of nosocomial infection (5.98% vs. 6.67%, p = 1.00) and 1‐year cumulative mortality (4.81% vs. 1.89%, p = 0.40) was comparable between the two groups. Conclusions: The antibiotics’ prophylactic use was not associated with 5‐day treatment failure or 6‐week mortality. Prophylactic use of antibiotics may not be routinely necessary in patients with Child A cirrhosis and AVB.

19 December 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
GLGuofeng Liu
Guofeng Liu
XFXiaoli Fan
Xiaoli Fan
LYLi Yang
Li Yang
XLXuefeng Luo
Xuefeng Luo